How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia
- https://doi.org/10.2991/chi.k.211119.001How to use a DOI?
- ALL; MRD; acute lymphoblastic leukemia; measurable residual disease; adult
Over the last decade the use of measurable residual disease (MRD) diagnostics in adult acute lymphoblastic leukemia (ALL) has expanded from a limited number of study groups in Europe and the United States to a world-wide application. In this review, we summarize the advantages and drawbacks of the current available techniques used for MRD monitoring. Through the use of three representative case studies, we highlight the advances in the use of MRD in clinical decision-making in the management of ALL in adults. We acknowledge discrepancies in MRD monitoring and treatment between different countries, reflecting differing availability, accessibility and affordability.
- © 2021 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - JOUR AU - Fiona Fernando AU - Harry Frederick Robertson AU - Sarah El-Zahab AU - Jiří Pavlů PY - 2021 DA - 2021/11/29 TI - How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia JO - Clinical Hematology International SP - 130 EP - 141 VL - 3 IS - 4 SN - 2590-0048 UR - https://doi.org/10.2991/chi.k.211119.001 DO - https://doi.org/10.2991/chi.k.211119.001 ID - Fernando2021 ER -